Retatrutide is a new medication in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in research studies. By activating these receptors, Retatrutide reduces hunger pangs, {promotesenergy expenditure, and ultimately results in significant slimming. While research is ongoing